

# Saphnelo™ (anifrolumab-fnia)



## Pharmacy Coverage Policy

**Effective Date:** December 15, 2021

**Revision Date:** November 22, 2023

**Review Date:** November 15, 2023

**Line of Business:** Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

**Policy Type:** Prior Authorization

Page: 1 of 3

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to [http://apps.humana.com/tad/tad\\_new/home.aspx](http://apps.humana.com/tad/tad_new/home.aspx) to verify that this is the current version before utilizing.

### Products Affected

Saphnelo intravenous solution

### Listed Indications

[Systemic Lupus Erythematosus \(SLE\)](#)

### Systemic Lupus Erythematosus (SLE)

#### Does the member meet all of the following criteria?

|             |                                                                                                                                         |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Criteria #1 | Has a diagnosis of moderate to severe systemic lupus erythematosus                                                                      |
| Criteria #2 | Prior to initiating therapy, the member is positive for autoantibodies relevant to SLE (e.g., ANA, anti-ds DNA, anti-Sm)                |
| Criteria #3 | Will be using in combination with standard treatment regimens (e.g. combination of prednisone, hydroxychloroquine, and/or azathioprine) |
| Criteria #4 | Does not have severe active lupus nephritis or severe active nervous system lupus                                                       |
| Criteria #5 | Prescribed by or in consultation with a provider who has expertise in treating systemic lupus erythematosus                             |

#### For continuation of therapy requests, does the member meet all of the following renewal criteria?

|                     |                                                                                                                                    |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Renewal Criteria #1 | Member meets the initial treatment criteria                                                                                        |
| Renewal Criteria #2 | Has demonstrated a response to Saphnelo (e.g. achieved low disease activity or improvement in signs and symptoms of the condition) |

#### Approval Duration

|         |                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------|
| Initial | Saphnelo (anifrolumab-fnia) will be approved in plan year durations or as determined through clinical review. |
|---------|---------------------------------------------------------------------------------------------------------------|

[Back to top](#)

### Background

This is a prior authorization policy about Saphnelo (anifrolumab-fnia).

- Systemic lupus erythematosus (SLE) is a complex, chronic, potentially life-threatening, autoimmune disease that is characterized by immunologic abnormalities resulting in systemic inflammation affecting multiple organs such as the skin, joints, kidney, lungs and central nervous system.
- SLE is difficult to diagnose because the symptoms are often mistaken for those of other diseases. The 2019 European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) include classification criteria for SLE which requires the presence of a positive antinuclear antibodies (ANA) as an entry criterion. Additive criteria consist of seven clinical (ie, constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and three immunologic (ie, antiphospholipid antibodies, complement proteins, SLE-specific antibodies) domains, each of which are weighted from 2 to 10. Patients accumulating 10 or more points are classified as having SLE.
- Warnings and Precautions:
  - Serious infections: serious and sometimes fatal infections have occurred in patients receiving Saphnelo. Saphnelo increases the risk of respiratory infections and herpes zoster. Avoid initiating treatment during an active infection. Consider benefit-risk if using in patients with severe or chronic infections. Consider interrupting therapy if patients develop a new infection.
  - Malignancy: consider the individual benefit-risk in patients with known risk factors for malignancy prior to prescribing Saphnelo.
  - Immunization: avoid use of live or live-attenuated vaccines in patients receiving Saphnelo.

## Saphnelo™ (anifrolumab-fnia)

Effective Date: 12/15/2021

Revision Date: 11/22/2023

Review Date: 11/15/2023

Line of Business: Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

Policy Type: Prior Authorization

Page: 2 of 3

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to [http://apps.humana.com/tad/tad\\_new/home.aspx](http://apps.humana.com/tad/tad_new/home.aspx) to verify that this is the current version before utilizing.

- Not recommended for use with other biologic therapies.

- For complete list of warnings, precautions and monitoring recommendations, see the product label.

Saphnelo (anifrolumab-fnia) is a type I interferon receptor antagonist.

Anifrolumab-fnia is a human monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs and inhibiting downstream inflammatory and immunological processes.

Saphnelo (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.

Saphnelo (anifrolumab-fnia) is available as 300 mg/2mL single dose vials.

### Provider Claim Codes

For medically billed requests, please visit [www.humana.com/PAL](http://www.humana.com/PAL). Select applicable Preauthorization and Notification List(s) for medical and procedural coding information.

### Medical Terms

Saphnelo; anifrolumab-fnia; systemic lupus erythematosus; intravenous; pharmacy

### References

1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78:1151-1159.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; URL: <http://clinicalpharmacology.com>. Updated periodically.
3. IBM Micromedex DRUGDEX (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com>. Updated periodically..
4. Lexi-Comp [database online]. Hudson, OH Lexi-comp, Inc.: URL <http://online.lexi.com>. Updated periodically.
5. Saphnelo [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; Revised September 2022

#### Disclaimer

State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at <http://www.cms.hhs.gov/>. The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise without permission

**Saphnelo™ (anifrolumab-fnia)**

Effective Date: 12/15/2021

Revision Date: 11/22/2023

Review Date: 11/15/2023

Line of Business: Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

Policy Type: Prior Authorization

Page: 3 of 3

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version.  
Refer to [http://apps.humana.com/tad/tad\\_new/home.aspx](http://apps.humana.com/tad/tad_new/home.aspx) to verify that this is the current version before utilizing.

from Humana.